APA (7th ed.) Citation

R, D., M, B., K, H., MT, E., R, B., M, S., . . . C, A. (2012). Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: In vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition. Leukemia & lymphoma, 53(8), 1501. https://doi.org/10.3109/10428194.2012.656625

Chicago Style (17th ed.) Citation

R, Dummer, et al. "Vorinostat Combined with Bexarotene for Treatment of Cutaneous T-cell Lymphoma: In Vitro and Phase I Clinical Evidence Supporting Augmentation of Retinoic Acid Receptor/retinoid X Receptor Activation by Histone Deacetylase Inhibition." Leukemia & Lymphoma 53, no. 8 (2012): 1501. https://doi.org/10.3109/10428194.2012.656625.

MLA (9th ed.) Citation

R, Dummer, et al. "Vorinostat Combined with Bexarotene for Treatment of Cutaneous T-cell Lymphoma: In Vitro and Phase I Clinical Evidence Supporting Augmentation of Retinoic Acid Receptor/retinoid X Receptor Activation by Histone Deacetylase Inhibition." Leukemia & Lymphoma, vol. 53, no. 8, 2012, p. 1501, https://doi.org/10.3109/10428194.2012.656625.